Last reviewed · How we verify
NCT05382910
A Study of MG-K10 in Subjects With Asthma
Phase 1, PHASE2 trial testing MG-K10 in Asthma in 180 participants. Status unknown.
20 December 2023
Quick facts
| Lead sponsor | Shanghai Mabgeek Biotech.Co.Ltd |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 180 |
| Start date | 5 July 2022 |
| Primary completion | 20 December 2023 |
| Estimated completion | 20 June 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- MG-K10
- Placebo
Conditions studied
- Asthma — all drugs for Asthma →
Sponsor
Shanghai Mabgeek Biotech.Co.Ltd — full company profile →
Who can join
Adults 18 to 75, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a phase Ib/II clinical trial conducted in Chinese adult asthmatic subjects to evaluate the preliminary efficacy and safety of MG-K10 humanized monoclonal antibody injection in the treatment of asthma.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways.
Eggel A, Pennington LF, Jardetzky TS. · · 2024 · cited 45× · PMID 39158477 · DOI 10.1111/imr.13380 -
Advances in Biologic Therapies for Allergic Diseases: Current Trends, Emerging Agents, and Future Perspectives.
Alska E, Łaszczych D, Napiórkowska-Baran K, Szymczak B, et al · · 2025 · cited 13× · PMID 40004611 · DOI 10.3390/jcm14041079 -
Phase Ib/II Study of Preliminary Efficacy, Safety and Pharmacodynamics of MG-K10, a Humanised Monoclonal Antibody Targeting IL-4Rα, in Adult Chinese Patients With Asthma.
Xian M, Shi X, Li R, Zhao L, et al · · 2026 · PMID 42212541 · DOI 10.1111/cea.70345
Verify or expand the search:
- PubMed search for NCT05382910
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of MG-K10
Trials testing the same drug.
- NCT05466877 — A Study of MG-K10 in Subjects With Atopic Dermatitis · Phase 2 · unknown
Other recruiting trials for Asthma
Currently open trials in the same condition.
- NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
- NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
- NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
- NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
- NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting
Other Shanghai Mabgeek Biotech.Co.Ltd trials
Trials by the same sponsor.
- NCT07103174 — A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis · Phase 2 · not yet recruiting
- NCT07054034 — Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects · Phase 2 · active not recruiting
- NCT06837922 — Clinical Trial of MG-K10 in Stage III of Moderate to Severe Asthma · Phase 3 · recruiting
- NCT06846385 — Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic · Phase 2, PHASE3 · recruiting
- NCT06026891 — Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis · Phase 3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05382910 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Mabgeek Biotech.Co.Ltd
- Last refreshed: 21 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05382910.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing